Artiva Biotherapeutics, Inc. (ARTV) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $20.50 (low: $18.00, high: $23.00), representing an upside of 125.3% from the current price $9.10.
Analysts estimate Earnings Per Share (EPS) of $-5.57 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.20 vs est $-5.57 (beat +6.7%). 2025: actual $-3.43 vs est $-3.43 (beat +0.1%). Analyst accuracy: 96%.
ARTV Stock — 12-Month Price Forecast
$20.50
▲ +125.27% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Artiva Biotherapeutics, Inc., the average price target is $20.50, with a high forecast of $23.00, and a low forecast of $18.00.
The average price target represents a +125.27% change from the last price of $9.10.
Highest Price Target
$23.00
Average Price Target
$20.50
Lowest Price Target
$18.00
ARTV Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Artiva Biotherapeutics, Inc. in the past 3 months
EPS Estimates — ARTV
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.20
vs Est –$5.57
▲ 7.2% off
2025
Actual –$3.43
vs Est –$3.43
▲ 0.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ARTV
90%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▼ 9.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
